SCHEMBL665155

SCHEMBL665155

O=C(O)c1ccc(C2CC2)c(Cl)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.57
SLC6A4 P31645 2/20 0.47
SLC6A2 P23975 1/20 0.47
SLC6A3 Q01959 1/20 0.47
CREBBP Q92793 1/20 0.47
KDM5A P29375 1/20 0.46
KDM4C Q9H3R0 1/20 0.46
KDM5B Q9UGL1 1/20 0.46
SRD5A2 P31213 2/20 0.46
KMO O15229 1/20 0.45
MRGPRX4 Q96LA9 1/20 0.44
TTR P02766 1/20 0.44
ALDH1A1 P00352 1/20 0.43
MAPT P10636 1/20 0.43
MCL1 Q07820 2/20 0.43
RARG P13631 2/20 0.42
RARB P10826 1/20 0.42
RORC P51449 3/20 0.42
ALOX15 P16050 1/20 0.42
SRD5A1 P18405 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13268997 0.93 KMO (0.54) TSHRSLC6A4SLC6A2SLC6A3CREBBP
SCHEMBL3902501 0.91 KMO (0.57) TSHRSLC6A4SLC6A2SLC6A3SRD5A2
SCHEMBL11674643 0.91 KMO (0.57) TSHRSLC6A4SLC6A2SLC6A3SRD5A2
SCHEMBL24213990 0.86 TSHR (0.46) TSHRSLC6A4SLC6A2SLC6A3CREBBP
SCHEMBL10148406 0.85 TSHR (0.57) TSHRSLC6A4SLC6A2SLC6A3CREBBP
SCHEMBL24959728 0.85 KMO (0.40) TSHRSLC6A4SLC6A2SLC6A3KDM5A
SCHEMBL10148390 0.82 RARG (0.56) TSHRSLC6A4SLC6A2SLC6A3CREBBP
SCHEMBL15535905 0.81 TSHR (0.45) TSHRSLC6A4SLC6A2SLC6A3KDM5A
SCHEMBL31386224 0.80 HTR2A (0.46) SLC6A4SLC6A2SLC6A3
SCHEMBL15536723 0.80 TSHR (0.44) TSHRSLC6A4SLC6A2SLC6A3KDM5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3760616-A1 4-METHYLDIHYDROPYRIMIDINONE COMPOUND AND MEDICINAL USE THEREOF Japan Tobacco Inc. (JP) 2021-01-06 EP disclosed
EP-2423182-A1 DIACYLETHYLENEDIAMINE COMPOUND Astellas Pharma Inc. (JP) 2012-02-29 EP disclosed
US-20120046292-A1 DIACYLETHYLENEDIAMINE COMPOUND ASTELLAS PHARMA INC. (JP) 2012-02-23 US disclosed
US-20120046292-A1 DIACYLETHYLENEDIAMINE COMPOUND ASTELLAS PHARMA INC. (JP) 2012-02-23 US disclosed
US-20120046292-A1 DIACYLETHYLENEDIAMINE COMPOUND ASTELLAS PHARMA INC. (JP) 2012-02-23 US disclosed
WO-2010122968-A1 DIACYLETHYLENEDIAMINE COMPOUND アステラス製薬株式会社 (JP) 2010-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120046292-A1 DIACYLETHYLENEDIAMINE COMPOUND DGAT1, DGAT2, DIMT1 TSHR 4189/4885SLC6A4 997/4885SLC6A2 428/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.